Exchange listing deficiency and compliance notices under 8-K Item 3.01.
HYPERION DEFI, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“September 2, 2025, the Company received a notice from the Staff indicating that the Company has regained compliance with the Minimum Equity Requirement.”
Next Technology Holding Inc. received a nasdaq delisting notice notice regarding other (rules 5101).
“August 25, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating Nasdaq’s view that the Company no longer has an operating business and is a “public shell” under Nasdaq Listing Rule 5101 and, as a result, unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), it would be subject to delisting. The Company disagrees with Nasdaq’s view regarding the Company’s status as a “public shell” and has appealed Nasdaq’s determination by submitting a hearing request form on September 2, 2025. On Septe”
Mersana Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“September 5, 2025, Mersana Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50.0 million. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq”
SOCIETY PASS INCORPORATED. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(2)).
“September 2, 2025, the Company received a letter (“Compliance Letter”) from Nasdaq indicating that, the Company has demonstrated compliance with the Equity Rule, and the Company is therefore in compliance with the Nasdaq Capital Market’s continued listing requirements. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of the Compliance Letter. If, within that one-year monitoring period, Nasdaq finds the Company again out of compliance with the Equity Rule, the Company will not be permitted to provide Nasdaq w”
VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
“September 2, 2025, the Company received an additional notification letter (the “Letter”) from the Staff indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) because the Company’s stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing. The Company’s stockholders’ deficit was $18,488 as of December 31, 2024, as reported in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 . The Letter also noted that, as of August 29, 2025, the Company did not meet the alternatives of marke”
VSEE HEALTH, INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
“August 28, 2025 (although as of the filing of this Current Report on Form 8-K, trading has not been suspended) . The Company filed an appeal with the Nasdaq Hearings Panel (the “Panel”), and a hearing before the Panel is scheduled to be held on September 9, 2025. The Staff’s determination to deny the Company’s request to continue listing on Nasdaq was based on the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Annual Report on Form 10-K for the fiscal year ended Decembe”
GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“September 2, 2025, the Company received a written notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that because the Company did not regain compliance with Nasdaq Listing Rule 5450(b)(2)(A), requiring that the Company maintain a minimum market value of its publicly held shares of $50,000,000 for 30 consecutive trading days, by September 1, 2025, Nasdaq will consider this deficiency in their decision regarding the Company’s continued listing on The Nasdaq Global Market. The Notice has no immediate effect on the listing of the Company’s ordinary shares on The Nasda”
DIH HOLDING US, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 26, 2025, the Company received a notice from the Staff of Nasdaq notifying the Company that due to the Company’s failure to timely file its Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), with the Securities and Exchange Commission (the “SEC”), and because the Company remains delinquent in filing its Form 10-K for the year ended March 31, 2025 (the “Form 10-K”, together with the Form 10-Q, the “Delinquent Reports”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Reports Rule”), which requires the t”
DIH HOLDING US, INC. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
“mission (the “SEC”), and because the Company remains delinquent in filing its Form 10-K for the year ended March 31, 2025 (the “Form 10-K”, together with the Form 10-Q, the “Delinquent Reports”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Reports Rule”), which requires the timely filing of all required periodic reports with the SEC. The Company plans to timely request a hearing before the Panel, and this request will stay the suspension of the Company’s Common Stock for a period of 15 days from the date of the reques”
New ERA Energy & Digital, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
“September 3, 2025, the Company received notice (the “Notice”) from the Staff indicating that the Company had not regained compliance with the MVLS Rule as of September 2, 2025, and that the Company was therefore subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least pending the ultimate conclusion of the hearing process. At the hearing, the Company intends to present its plan to evidence compliance with the appl”
Peraso Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 5, 2025, Peraso Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on September 4, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until March 4, 2026, in which to”
Borealis Foods Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4), 10A-3).
“August 29, 2025, Borealis Foods Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the audit committee composition requirement set forth in Nasdaq Listing Rule 5605(c)(2)(A) (the “Nasdaq Composition Requirements”) due to the resignation of Kanat Mynzhanov from the Company’s board of directors (the “Board”). As described in the Company’s Current Report on Form 8-K, which was filed with the SEC on January 6, 2025. Specifically, when the Notice was issued, the”
SYNTEC OPTICS HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“August 29, 2025, Syntec Optics Holdings, Inc. (the “Company”) received an additional delinquency notification letter from the Nasdaq Listing Qualifications (“Nasdaq”) notifying the Company that because it has not filed Company’s Form 10-Q for the period ended June 30, 2025 and it remains delinquent in filing its Form 10-K for the period ended December 31, 2024 and its Form 10-Q for the period ended March 31, 2025, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Previously, Nasdaq had granted the Company an exception until August 20, 2025, to file its delinquent Form 10-K”
CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b), 5815(d)(4)(B)).
“August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “ Stockholders’ Equity Requirement ”) for continued listing on the Nasdaq Capital Market (“ Nasdaq ”) set forth in Nasdaq Rule 5550(b). As previously disclosed, the Company previously had been out of compliance with Nasdaq continued listing requirements until, on May 7”
Spirit Aviation Holdings, Inc. received a nyse_american delisting notice notice regarding other (rules 1003(c)(iii)).
“September 2, 2025, Spirit Aviation Holdings, Inc. (the “Company”) received a notice from the staff of NYSE Regulation (“NYSE Regulation”) that it had determined to commence proceedings to delist the common stock, par value $0.0001, of the Company (the “Common Stock”) from NYSE American LLC (“NYSE American”) and that trading in the Common Stock was suspended immediately on September 2, 2025. NYSE Regulation reached its decision that the Company is no longer suitable for listing pursuant to Section 1003(c)(iii) of the NYSE American Company Guide after the Company disclosed in its August 29, 2025”
ADIAL PHARMACEUTICALS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“September 2, 2025, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “September 2025 Nasdaq Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company is eligible for an additional 180 calendar days, or until March 2, 2026, to regain compliance with Nasdaq’s requirement to maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on Nasdaq (the “Minimum Bid Price Requirement”), following the expiration of the initial 180 calendar day period granted to the Company by Nasdaq to regain c”
Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“August 28, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with the minimum Market Value of Listed Securities (“ MVLS ”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Requirement ”). The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c”
Nuvve Holding Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)(iv)).
“August 27, 2025, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Rule”). Further, the Notice stated that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company was”
Nuvve Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“August 27, 2025, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Rule”). Further, the Notice stated that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company was”
urban-gro, Inc. received a nasdaq delisting notice notice regarding other (rules 5250(c)(1), 5550(b)(1)).
“Stock for a period of 15 days from the date of the request. In connection with this request, the Company plans to also request a stay of the suspension pending the hearing (the “Additional Stay”). There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rules 5550(a)(2), 5250(c)(1) and/or 5550(b)(1), or will otherwise be in compliance with other applicable Nasdaq Listing Rules, that the request for the Additional Stay will be granted, or that the Company’s appeal of the delisting determination will be successful.”
urban-gro, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“August 28, 2025, the Company received a determination letter (the “Determination”) from Nasdaq stating that Nasdaq had determined that the Company did not regain compliance with the Minimum Bid Requirement by August 25, 2025. The Determination stated that the failure to comply with the Minimum Bid Requirement during the compliance period would serve as an additional basis for delisting the Company’s securities from the Nasdaq Capital Market and would be considered by a Hearings Panel (the “Panel”), in addition to the Company’s failure to comply with (i) Nasdaq Listing Rule 5250(c)(1) due to th”
T3 Defense Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(3)(A), 5810(c)(3)(C)).
“August 28, 2025, Nukkleus Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon its review of the Company’s market value of listed securities (“MVLS”) for the last 30 consecutive business days from July 10, 2025 to August 27, 2025, the Company no longer meets Nasdaq Listing Rule 5450(b)(2)(A), which requires companies listed on the Nasdaq Global Market to maintain a minimum MVLS of $50,000,000. The Notice further stated that the Company also does not meet the requirements”
Context Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the “Extension Deadline”), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that”
ScanTech AI Systems Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 26, 2025, ScanTech AI Systems Inc. (the “Company”) received a deficiency letter (the “Periodic Report Notice”) from Nasdaq Listing Qualifications of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Quarterly Report”). The Periodic Report Notice has no immediate effect on the listing of the Company’s common stock on The Na”
Enlightify Inc. received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).
“August 27, 2025, the New York Stock Exchange (“NYSE”) notified Enlightify Inc. (the “Company”) that the 30-trading-day average closing price of the Company’s common stock had fallen below $1.00 per share, the minimum average share price required for continued listing of the Company’s common stock on the NYSE under Rule 802.01C of the NYSE Listed Company Manual. Under NYSE rules, the Company has 10 business days from its receipt of the notification to inform the NYSE of its intent to cure the share price deficiency to return to compliance with this continued listing standard. In order to return”
PATHWARD FINANCIAL, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 26, 2025, Pathward Financial, Inc. ("Pathward Financial" or the “Company”) received an expected notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file its Quarterly Report on Form 10-Q (“Form 10-Q”) for the fiscal quarter ended June 30, 2025, as described more fully in the Company's Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission (the “SEC”) on Aug”
BOLLINGER INNOVATIONS, INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“for the period ended June 30, 2025, as filed with the Securities and Exchange Commission on August 15, 2025, the Company believes that as of August 14, 2025, the Company’s stockholders' equity exceeded $2.5 million, which is an alternative standard to the MVLS Listing Rule under Nasdaq Listing Rule 5550(b). Although there can be no assurance that the Panel will grant the Company’s request for continued listing on The Nasdaq Capital Market, the delisting proceedings will be stayed and the Company’s common stock will continue to be listed on The Nasdaq Capital Market pending resolution of the ap”
Rallybio Corp received a nasdaq noncompliance notice notice regarding minimum bid price.
“February 24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business days (the “Notice”), as required for continued listing on the Nasdaq. Pursuant to Nasdaq’s Listing Rules, the Company had until August 25, 2025 (the “Initial Compliance Date”) to regain compliance with the minimum closing bid price requirement. As of the Initial Complian”
Envoy Medical, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“August 26, 2025, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period. The determination letter informed the Company that it can request a hearing regarding Nasdaq’s determination with a Hearings Panel (the “Panel”) by September 2, 2025 to discuss how the Company believes it will regain compliance and why the Company believes the Hearing Panel should grant an extension. If the Company did not make a request to the Hearings Panel, the trading of the Company’s securities would be”
Century Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“August 27, 2025, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until February 23, 2026 (the “ Extended Compliance Date ”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse sto”
DIH HOLDING US, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“mission (the “SEC”), and because the Company remains delinquent in filing its Form 10-K for the year ended March 31, 2025 (the “Form 10-K”, together with the Form 10-Q, the “Delinquent Reports”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. Under Nasdaq rules, the Company has until September 29, 2025 to submit a plan to regain compliance with respect to the Delinquent Reports. If the Company is unable to file the Delinquent Reports”
ECD Automotive Design, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“(the “Commission”) on February 25, 2025, the Nasdaq Listing Qualifications Department (the “Staff”) notified ECD Automotive Design, Inc. (the “Company”) that the market value of its listed securities had been below the minimum $35,000,000 required for continued listing as set forth in Listing Rule 5550(b)(2) (the “Rule”) for the previous 30 consecutive trading days. Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until August 25, 2025, to regain compliance with the Rule. On August 26, 2025, the Company received another notice (the “MVLS”
Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 26, 2025, Enveric Biosciences, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, r”
CaliberCos Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 27, 2025, CaliberCos Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, based on the Company’s stockholders’ equity of $(17,604,000) as reported on its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholder Equity Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of”
Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“August 25, 2025, Iterum Therapeutics plc (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasdaq Capital Ma”
Next Technology Holding Inc. received a nasdaq delisting notice notice regarding other (rules 5101).
“) Co., Ltd.” in July, 2024. The Staff also considered the Company’s quarterly reports on Form 10-Q filed on May 9, 2025 and August 8, 2025, respectively, which indicated that the Company has not generated any revenue in 2025. Based on the Staff’s review of the Company and pursuant to Nasdaq Listing Rule 5101, Nasdaq believes that the Company no longer has an operating business and is therefore a “public shell,” and that the continued listing of its common stock is no longer warranted. The Notice further advised that, unless the Company timely requests a hearing before a Hearings Panel (the “Pa”
Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“August 22, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum of $10.0 million in stockholders’ equity, as required by Nasdaq Listing Rule 5450(b)(1)(A) for continued listing on The Nasdaq Global Select Market. As stated in the Letter, the Company reported stockholders’ equity of $7,069,000 in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.”
Imunon, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
DNA X, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).
“August 22, 2025, Sonim Technologies, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was $1,334”
American Strategic Investment Co. received a nyse deficiency notice notice regarding market value (rules 802.01B).
“August 26, 2025, American Strategic Investment Co. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (“NYSE”) that the Company did not presently satisfy the NYSE’s continued listing standards under Section 802.01B of the NYSE Listed Company Manual (the “Manual”), which requires the Company’s 30-trading day average market capitalization to be not less than $50 million and the Company’s stockholders’ equity to be not less than $50 million. As set forth in the Notice, as of August 25, 2025, the Company’s 30-trading day average market capitalization was appr”
ZeroStack Corp. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(c)(2)(A)).
“August 26, 2025, Nasdaq was informed that because of Mr. Wolkin's passing, the Company is no longer in compliance with certain Corporate Governance Requirements as set forth in Nasdaq Listing Rule 5605. Pursuant to Nasdaq Listing Rule 5605(b)(1), a majority of the Board of a listed company must be comprised of Independent Directors. With Mr. Wolkin's passing, the Board is currently comprised of only four members, Sammy Dorf, Clifford Starke, Edward Woo and Manfred Leventhal. Only two of the four, Mr. Woo and Mr. Leventhal, qualify as Independent Directors. Therefore, the Company's Board is no”
BullFrog AI Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 21, 2025, BullFrog AI Holdings, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, based on the Company’s stockholders’ equity of $2,188,110 as reported on its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholder Equity Requirement”). The Nasdaq deficiency letter has no immediate effect on the lis”
Brand Engagement Network Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“August 21, 2025 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to file the Quarterly Report timely. The Company has 60 calendar days from August 21, 2025, or until October 20, 2025, to regain compliance by filing the Quarterly Report or to submit a plan to Nasdaq to regain compliance with the Nasdaq Listing Rules. The Company intends to file the Quarterly Report as soon as possible. If the Company is unable to file the Quarterly Report by October 20, 2025, it intends to submit a pla”
Four Leaf Acquisition Corp received a nasdaq deficiency notice notice regarding late filing.
“August 21, 2025, Four Leaf Acquisition Corporation. (“FORL” or the “Company”) received a notice (the “Notice”) from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had failed to file its Quarterly Report on Form 10-Q for the year ended June 30, 2025 (the “Form 10-Q”). Nasdaq previously issued notices regarding the Company’s non-compliance with Nasdaq’s listing rules as basis for delisting, and the Company requested an appeal of this determination, and was granted an extension. This Notice serves as additional basis fo”
DT Cloud Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5450(b)(2)(B), 5810(c)(2)(c)).
“August 25, 2025, DT Cloud Acquisition Corporation (the “Company”) received deficiency letters (each a “Notice” and together, the “Notices”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that: ● for the last 30 consecutive business days, the minimum Market Value of Listed Securities, as defined by Nasdaq (“MVLS”), of the Company has been below the minimum $50 million requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”); and ● the number of publicly held sh”
DT Cloud Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(c), 5450(b)(2)(B), 5810(c)(2)(c)).
“August 25, 2025, DT Cloud Acquisition Corporation (the “Company”) received deficiency letters (each a “Notice” and together, the “Notices”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that: ● for the last 30 consecutive business days, the minimum Market Value of Listed Securities, as defined by Nasdaq (“MVLS”), of the Company has been below the minimum $50 million requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”); and ● the number of publicly held sh”
Greenwave Technology Solutions, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“August 22, 2025, to evidence compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). On August 22, 2025, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 (the “Q2 Form 10-Q”, and together with the Q1 Form 10-Q, the “Delinquent Filings”). The Staff informed the Company that is has until September 8, 2025 to submit an updated plan to regain compliance with the Rule. If the Staff accepts the Company’s revised plan to regain comp”
Cambium Networks Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 25, 2025, Cambium Networks Corporation (the “Company”) received a delinquency letter (the “delinquency notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the period ended June 30, 2025. In the delinquency notice Nasdaq confirmed that the Company has until October 13, 2025 to file all of its delinquent reports, including its delinquent Annual Report on Form”
Wetouch Technology Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 21, 2025, Wetouch Technology Inc., a Nevada corporation (the “Company” or “Wetouch”), received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the Company had not yet filed its Form 10-Q for the period ended June 30, 2025 (the “2 nd Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”). Previously, Staff had granted the”
Expion360 Inc. received a nasdaq compliance regained notice regarding late filing (rules 5550(b)(1)).
“August 20, 2025, the Company received a notification letter (the “ Notice ”) from the Nasdaq Listing Qualifications department of The Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that the stockholders’ equity balance reported in the Q2 Quarterly Report was below the $2.5 million required minimum for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “ Equity Rule ”). The Notice also provided that the Company has 45 calendar days to submit a plan to regain compliance. However, the Company believes that, as a result of the positive impact”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.